Overview

A Study to Investigate the Disposition of Radio-labeled AVE8062 Compound Administered as a 30-minute IV Infusion to Patients With Advanced Solid Tumor

Status:
Completed
Trial end date:
2011-09-01
Target enrollment:
Participant gender:
Summary
Primary Objectives: - To determine the excretion balance and systemic exposure of radioactivity after intravenous infusion of [14C]-AVE8062 to humans - To determine the pharmacokinetics of AVE8062 and RPR258063 and their contribution to overall exposure - To collect samples to determine the metabolic pathways of AVE8062 and identify the chemical structures of the main metabolites Secondary Objective: - To assess the safety profile of the drug
Phase:
Phase 1
Details
Lead Sponsor:
Sanofi